Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Schizophrenia Research|June 5, 2012
Response trajectories in "real-world" naturalistically treated schizophrenia patientsRebecca Schennach, Sebastian Meyer, Florian Seemüller, et al.International Journal of Methods in Psychiatric Research|July 17, 2015
Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methodsRebecca Schennach, Hans-Jürgen Möller, Michael Obermeier, et al.Psychiatry Research|March 17, 2012
One-year functional outcomes of naturalistically treated patients with schizophreniaIlja Spellmann, Michael Riedel, Rebecca Schennach, et al.European Archives of Psychiatry and Clinical Neuroscience|August 30, 2019
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.Pharmacopsychiatry|May 16, 2017
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?Rebecca Schennach, Michael Obermeier, Florian Seemüller, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 25, 2021
Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depressionMaria S Simon, Carmen Schiweck, Gara Arteaga-Henríquez, et al.European Archives of Psychiatry and Clinical Neuroscience|October 28, 2016
Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studiesIlja Spellmann, Rebecca Schennach, Florian Seemüller, et al.Schizophrenia Research|May 30, 2019
Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depressionRebecca Schennach, Michael Obermeier, Ilja Spellmann, et al.Schizophrenia Bulletin|July 20, 2022
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With SchizophreniaStephan Heres, Joachim Cordes, Sandra Feyerabend, et al.Pharmacopsychiatry|November 4, 2020
Review and Consensus on Pharmacogenomic Testing in PsychiatryChad A Bousman, Susanne A Bengesser, Katherine J Aitchison, et al.Pageof 9